Home LiteratureArticle Details
PMID: 1946358 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 88 ·No. 21 ·1991-11-01 ·Pages 9448-52

Hart MK, Weinhold KJ, Scearce RM, Washburn EM, Clark CA, Palker TJ, Haynes BF

Abstract

The generation of antiviral cytotoxic T lymphocytes (CTLs) is a critical component of the immune response to viral infections. A safe and nontoxic vaccine for AIDS would optimally use a carrier-free synthetic peptide immunogen containing only components of HIV necessary for induction of protective immune responses. We report that hybrid synthetic peptides containing either a HIV envelope gp120 T-cell determinant (T1) or the envelope gp41 fusion domain (F) N-terminal to HIV CTL determinants are capable of priming murine CD8+, major histocompatibility complex class I-restricted anti-HIV CTLs in vivo. These data demonstrate that carrier-free, nonderivatized synthetic peptides can be used in vivo to induce anti-HIV CTL responses.

MeSH Terms
Amino Acid Sequence Animals CD8 Antigens/analysis H-2 Antigens/immunology HIV Antigens/chemistry HIV Envelope Protein gp120/chemistry,immunology HIV-1/immunology Immunologic Memory Major Histocompatibility Complex Mice Mice, Inbred BALB C Mice, Inbred C57BL Molecular Sequence Data Peptides/immunology T-Lymphocytes, Cytotoxic/immunology
Chemicals
CD8 Antigens H-2 Antigens HIV Antigens HIV Envelope Protein gp120 Peptides
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Hart M K
Department of Medicine, Duke University Medical Center, Durham, NC 27710.
Weinhold K J
Scearce R M
Washburn E M
Clark C A
Palker T J
Haynes B F
References (40)
40 references, click to expand
  1. The expression of major histocompatibility antigens under metallothionein gene promoter control.
    J Immunol. 1985 Mar;134(3):1999-2003 PMID: 3918115
  2. Analysis of host-virus interactions in AIDS with anti-gp120 T cell clones: effect of HIV sequence variation and a mechanism for CD4+ cell depletion.
    Cell. 1988 Aug 12;54(4):561-75 PMID: 2969774
  3. A synthetic vaccine constructed by copolymerization of B and T cell determinants.
    Eur J Immunol. 1987 Feb;17(2):269-73 PMID: 2435562
  4. Prospects for the control of AIDS by immunizing seropositive individuals.
    Nature. 1987 Jun 11-17;327(6122):473-6 PMID: 3587367
  5. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
    Proc Natl Acad Sci U S A. 1987 Jun;84(12):4249-53 PMID: 2438696
  6. Distinguishable pathways of viral antigen presentation to T lymphocytes.
    Immunol Res. 1986;5(4):294-304 PMID: 3298467
  7. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.
    Cell. 1987 Jul 31;50(3):327-8 PMID: 3496970
  8. Cytotoxic T lymphocytes against a soluble protein.
    Nature. 1987 Oct 1-7;329(6138):449-51 PMID: 2443853
  9. Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.
    Proc Natl Acad Sci U S A. 1988 Mar;85(5):1610-4 PMID: 2449694
  10. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  11. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection.
    Lancet. 1988 Apr 9;1(8589):790-4 PMID: 2895317
  12. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3105-9 PMID: 2452443
  13. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  14. HIV infection. Why the long latent period?
    Nature. 1990 Nov 29;348(6300):388 PMID: 1978928
  15. Vaccination for disease.
    Science. 1991 Jan 11;251(4990):195-8 PMID: 1824801
  16. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  17. Peptide-induced antiviral protection by cytotoxic T cells.
    Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):991-3 PMID: 1992491
  18. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.
    Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2283-7 PMID: 1848698
  19. T cells can present antigens such as HIV gp120 targeted to their own surface molecules.
    Nature. 1988 Aug 11;334(6182):530-2 PMID: 2841610
  20. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
    J Immunol. 1989 May 15;142(10):3612-9 PMID: 2469721
  21. Identification of the fusion peptide of primate immunodeficiency viruses.
    Science. 1989 May 12;244(4905):694-7 PMID: 2541505
  22. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.
    J Immunol. 1989 Aug 15;143(4):1094-100 PMID: 2787356
  23. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  24. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein.
    J Exp Med. 1989 Dec 1;170(6):2023-35 PMID: 2479705
  25. Immunology. Stimulating killer cells.
    Nature. 1989 Nov 30;342(6249):478-9 PMID: 2586621
  26. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.
    Nature. 1989 Nov 30;342(6249):561-4 PMID: 2586628
  27. Vaccine engineering: enhancement of immunogenicity of synthetic peptide vaccines related to hepatitis in chemically defined models consisting of T- and B-cell epitopes.
    Proc Natl Acad Sci U S A. 1989 Dec;86(23):9084-8 PMID: 2480595
  28. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.
    J Virol. 1990 May;64(5):2448-51 PMID: 2182912
  29. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.
    Nature. 1990 Apr 26;344(6269):873-5 PMID: 2184369
  30. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.
    J Exp Med. 1990 May 1;171(5):1815-20 PMID: 1692084
  31. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.
    Science. 1990 Aug 24;249(4971):932-5 PMID: 2392685
  32. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
    J Immunol. 1990 Oct 15;145(8):2677-85 PMID: 1698859
  33. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601 PMID: 1700435
  34. Polarity of immunogens: implications for vaccine design.
    Eur J Immunol. 1990 Oct;20(10):2363-6 PMID: 1700756
  35. Immunology. Oh to be twenty seven again.
    Nature. 1991 Jun 13;351(6327):523 PMID: 2046762
  36. Mode of insertion into a lipid membrane of the N-terminal HIV gp41 peptide segment.
    AIDS Res Hum Retroviruses. 1988 Apr;4(2):83-90 PMID: 3259143
  37. The transmission of AIDS: the case of the infected cell.
    JAMA. 1988 May 27;259(20):3037-8 PMID: 3285042
  38. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
    Proc Natl Acad Sci U S A. 1988 Jun;85(12):4478-82 PMID: 2454471
  39. Preferential pairing of T-B specificities in the same antigen: the concept of directional help.
    Vaccine. 1988 Apr;6(2):94-8 PMID: 2455389
  40. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.
    Cell. 1986 Mar 28;44(6):959-68 PMID: 2420472
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.88.21.9448
Published
1991-11-01
Pages
9448-52
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC52735
Subset
IM
Grants
PHS HHS · A128662 · United States
NCI NIH HHS · CA28936 · United States
NCI NIH HHS · CA43447 · United States
External Links
PubMed source DOI: 10.1073/pnas.88.21.9448 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2